Liver Cancer
Conditions
Brief summary
Fibroblast activation protein (FAP) is a serine protease that belongs to the dipeptidyl peptidase-IV (DPP-IV) family located in fbroblast membranes. FAP is overexpressed in the cancer-associated fbroblasts (CAFs) of 90% of epithelial carcinomas, including primary and metastatic liver cancer. We aim to conduct a prospective study to investigate the diagnostic perfoemance of 18F-FAPI PET/CT in evaluating suspicious liver mass without FDG avidity.
Detailed description
Fibroblast activation protein (FAP) is a serine protease that belongs to the dipeptidyl peptidase-IV (DPP-IV) family located in fbroblast membranes. FAP is overexpressed in the cancer-associated fbroblasts (CAFs) of 90% of epithelial carcinomas, including primary and metastatic liver cancer. Therefore, FAP-targeted radiopharmaceuticals can be considered a promising approach for visualizing CAFs. CAFs are crucial components of the tumor stroma, promote the growth of cancer cells, and are associated with poor prognosis. Currently, 18F-labelled fbroblast activation protein inhibitor 18F-FAPI has shown promising diagnostic value in many types of tumors, especially those in which are not avid for 18F-FDF , and several studies have demonstrated that 18F-FAPI PET/CT is superior to 18F-FDG PET/CT for detecting liver cancer and has lower tracer uptake in normal liver tissue. We aim to conduct a prospective study to investigate the diagnostic performance of 18F-FAPI PET/CT in evaluating suspicious liver mass without FDG avidity.
Interventions
DIAGNOSTIC_TESTFAPI PET
Drug: 18F-FAPI 18F-FAPI were injected into the patients before the PET/CT scans
Sponsors
Jilin University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients with suspected liver malignant lesions based on traditional diagnostic imaging (CT or MRI or ultrasound) and clinical symptoms; * patients underwent \[18F\]FDG PET/CT with negative findings (suspicious primary and/or metastatic lesions were hypo- or isometabolic on \[18F\]FDG PET/CT); * patients who agreed to undergo \[18F\]FAPI PET/CT scans within 1 week.
Exclusion criteria
* pregnancy; * age\<18 years old; * patients with chemo/radio/targeted therapy before scanning; * inability to provide informed consent (signed by participant, parent, or legal representative).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic performance of FAPI PET | 1 year | Sensitivity and specificity in detecting liver cancer |
Countries
China
Contacts
Primary ContactShi Gao [gshi]
Backup ContactJi Bin [jbin]
Outcome results
None listed